HRP20202032T1 - Probe za snimanje huntingtonovog proteina - Google Patents

Probe za snimanje huntingtonovog proteina Download PDF

Info

Publication number
HRP20202032T1
HRP20202032T1 HRP20202032TT HRP20202032T HRP20202032T1 HR P20202032 T1 HRP20202032 T1 HR P20202032T1 HR P20202032T T HRP20202032T T HR P20202032TT HR P20202032 T HRP20202032 T HR P20202032T HR P20202032 T1 HRP20202032 T1 HR P20202032T1
Authority
HR
Croatia
Prior art keywords
dihydro
isoindol
pyridin
optionally substituted
methoxy
Prior art date
Application number
HRP20202032TT
Other languages
English (en)
Croatian (hr)
Inventor
Celia Dominguez
John Wityak
Jonathan Bard
Christopher John Brown
Thomas Martin KRÜLLE
Daniel CLARK-FREW
Sarah HAYES
Original Assignee
Chdi Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation, Inc. filed Critical Chdi Foundation, Inc.
Publication of HRP20202032T1 publication Critical patent/HRP20202032T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
HRP20202032TT 2014-08-29 2015-08-28 Probe za snimanje huntingtonovog proteina HRP20202032T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043644P 2014-08-29 2014-08-29
EP15836970.2A EP3186241B1 (en) 2014-08-29 2015-08-28 Probes for imaging huntington protein
PCT/US2015/047396 WO2016033436A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (1)

Publication Number Publication Date
HRP20202032T1 true HRP20202032T1 (hr) 2021-02-19

Family

ID=55400644

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20202032TT HRP20202032T1 (hr) 2014-08-29 2015-08-28 Probe za snimanje huntingtonovog proteina

Country Status (20)

Country Link
US (2) US11071793B2 (enExample)
EP (1) EP3186241B1 (enExample)
JP (3) JP2017527559A (enExample)
KR (1) KR102410760B1 (enExample)
CN (2) CN107074817B (enExample)
AU (1) AU2015308765B2 (enExample)
BR (1) BR112017004136B1 (enExample)
CA (1) CA2959531C (enExample)
DK (1) DK3186241T3 (enExample)
EA (1) EA037275B1 (enExample)
ES (1) ES2841746T3 (enExample)
HR (1) HRP20202032T1 (enExample)
HU (1) HUE052892T2 (enExample)
IL (1) IL250805B (enExample)
MX (2) MX383202B (enExample)
PL (1) PL3186241T3 (enExample)
PT (1) PT3186241T (enExample)
SG (1) SG11201701578YA (enExample)
SI (1) SI3186241T1 (enExample)
WO (1) WO2016033436A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
US10865201B2 (en) 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
EP3509587B1 (en) 2016-09-12 2023-12-06 Valo Health, Inc. Monocyclic compounds useful as gpr120 modulators
WO2020176424A1 (en) 2019-02-25 2020-09-03 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
US11992535B2 (en) 2019-12-18 2024-05-28 Chdi Foundation, Inc. Compounds and probes for imaging huntingtin protein
BR112022025238A2 (pt) * 2020-06-11 2023-02-14 Chdi Foundation Inc Compostos heterocíclicos e agentes de imageamento para formar imagem da proteína huntingtina
WO2022216947A1 (en) * 2021-04-08 2022-10-13 Chdi Foundation, Inc. Isoindolinone compounds and imaging agents for imaging huntingtin protein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726197A (en) * 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
IL146455A0 (en) 1999-06-10 2002-07-25 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
KR101011657B1 (ko) * 2002-03-01 2011-01-28 다케다 야쿠힌 고교 가부시키가이샤 항우울제
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
EP2215074B1 (en) * 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びppar活性化剤
WO2010104324A2 (ko) * 2009-03-10 2010-09-16 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를 가지는 할로겐화 이소인돌론 화합물, 및 이의 제조 방법 및 용도
BR112014026283B1 (pt) * 2012-04-25 2022-08-02 Raqualia Pharma Inc Compostos da fórmula (i), (ii), (iii), uso dos mesmos, composição farmacêutica, e processo para a preparação de uma composição farmacêutica
WO2015054317A1 (en) * 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
EP3186233B8 (en) 2014-08-29 2021-09-29 CHDI Foundation, Inc. Probes for imaging huntingtin protein
EA037275B1 (ru) 2014-08-29 2021-03-03 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
US11104691B2 (en) 2014-08-29 2021-08-31 Chdi Foundation, Inc. Probes for imaging huntingtin protein
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Also Published As

Publication number Publication date
US12036291B2 (en) 2024-07-16
KR102410760B1 (ko) 2022-06-20
AU2015308765A1 (en) 2017-03-23
JP2017527559A (ja) 2017-09-21
EA037275B1 (ru) 2021-03-03
IL250805A0 (en) 2017-04-30
MX383202B (es) 2025-03-13
US20210379211A1 (en) 2021-12-09
AU2015308765B2 (en) 2020-06-04
CA2959531C (en) 2023-01-10
JP2020079272A (ja) 2020-05-28
MX2017002704A (es) 2017-10-23
WO2016033436A1 (en) 2016-03-03
US20170281804A1 (en) 2017-10-05
CA2959531A1 (en) 2016-03-03
HUE052892T2 (hu) 2021-05-28
MX2021005891A (es) 2021-06-23
US11071793B2 (en) 2021-07-27
PT3186241T (pt) 2021-01-08
ES2841746T3 (es) 2021-07-09
BR112017004136B1 (pt) 2022-05-03
JP7042940B2 (ja) 2022-03-28
CN118005611A (zh) 2024-05-10
EP3186241A1 (en) 2017-07-05
CN107074817B (zh) 2023-12-15
BR112017004136A2 (pt) 2017-12-12
SI3186241T1 (sl) 2021-03-31
JP2021088584A (ja) 2021-06-10
SG11201701578YA (en) 2017-03-30
EP3186241B1 (en) 2020-10-07
PL3186241T3 (pl) 2021-05-17
EA201790432A1 (ru) 2017-09-29
IL250805B (en) 2020-08-31
EP3186241A4 (en) 2018-04-18
CN107074817A (zh) 2017-08-18
KR20170047348A (ko) 2017-05-04
DK3186241T3 (da) 2021-01-11
JP6843282B2 (ja) 2021-03-17

Similar Documents

Publication Publication Date Title
HRP20202032T1 (hr) Probe za snimanje huntingtonovog proteina
JP2017527559A5 (enExample)
JP2017529340A5 (enExample)
EP3410919A4 (en) DENTAL IMAGING APPARATUS AND METHOD FOR RECORDING PHOTOGRAPHIC IMPRESSIONS
JP2016506958A5 (enExample)
JP2016505614A5 (enExample)
HRP20211156T1 (hr) Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
HRP20171078T1 (hr) Derivati arilmetoksi izoindolina i pripravci koji ih sadrže, te postupci njihove uporabe
JP2016506960A5 (enExample)
ME02452B (me) Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti
JP2017538773A5 (enExample)
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
HRP20210641T1 (hr) Deuterirani heterociklični spojevi i njihova uporaba kao sredstva za kontrastiranje
EP2781082A4 (en) POSITIONING DEVICE FOR GENERATING PHOTOS AND VIDEO IMAGES AND RECORDING SYSTEM USING THIS DEVICE
JP2017520540A5 (enExample)
RU2015120556A (ru) Ингибиторы гликозидаз и их применения
BR112017018173A2 (pt) comprimido, método de estabilização, e, preparação sólida
HRP20200796T1 (hr) Sredstvo koje sadržava derivat alkil etera ili njegove soli namijenjen za poboljšanje učinka oporavka nakon ozljede živca
RU2017145922A (ru) МОДУЛЯТОРЫ ROR ГАММА(RORy)
RU2016112547A (ru) Имидазо[1,2-а]пиридин-7-амины в качестве средств визуализации
JP2014510147A5 (enExample)
EP3851499A4 (en) INK SET AND IMAGE RECORDING PROCESS AND INK COMPOSITION
MX2018016279A (es) Compuestos para formacion de imagenes de agregados de proteinas tau.